ProStrakan Group plc, the international specialty pharmaceutical company, announces that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has issued a marketing authorisation for Abstral (for breakthrough cancer pain).
The details can be read here.
No comments:
Post a Comment